KeyCorp Cuts Certara (NASDAQ:CERT) Price Target to $15.00

Certara (NASDAQ:CERT - Free Report) had its target price reduced by KeyCorp from $18.00 to $15.00 in a research note released on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research analysts have also recently weighed in on the stock. JMP Securities reiterated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Barclays upgraded shares of Certara from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Morgan Stanley started coverage on shares of Certara in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $16.00 price objective on the stock. Finally, Robert W. Baird boosted their price objective on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.29.

Certara Stock Performance

NASDAQ CERT traded up $0.23 during trading hours on Monday, hitting $10.64. 531,764 shares of the company's stock traded hands, compared to its average volume of 1,487,327. The business's fifty day moving average price is $11.35 and its two-hundred day moving average price is $11.86. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $1.73 billion, a P/E ratio of -532.50 and a beta of 1.43. Certara has a 52 week low of $8.64 and a 52 week high of $16.93.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. Certara had a negative net margin of 0.67% and a positive return on equity of 5.05%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. Equities research analysts predict that Certara will post 0.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CERT. AdvisorNet Financial Inc bought a new position in shares of Certara in the second quarter worth about $25,000. Versant Capital Management Inc grew its holdings in Certara by 218.8% during the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after acquiring an additional 1,866 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Certara during the 1st quarter worth about $31,000. Wells Fargo & Company MN grew its holdings in Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares in the last quarter. Finally, AlphaQuest LLC bought a new position in Certara during the 1st quarter worth about $39,000. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.